Clinical Microbiology and Antimicrobial Chemotherapy. 2008; 10(4):322-332
Carbapenems are the most appropriate antimicrobials for empiric and pathogen-directed monotherapy in most severe and life-threatening infections in pediatric patients. It can be explained by broadest spectrum of activity, including multidrug resistant pathogens, stability against b-lactamases, and low incidence of adverse drug reactions. In addition, use of carbapenems as monotherapy may reduce risk of adverse drug interactions. Both many clinical trials and extensive clinical use in children with severe infections (bacterial meningitis, pneumonia, sepsis, cystic fibrosis, intra-abdominal infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, febrile neutropenia) demonstrated high efficacy and favorable safety profile of meropenem.